Patents by Inventor Ivan Perrot

Ivan Perrot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD73 blockade
    Patent number: 11958907
    Abstract: This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5? nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: April 16, 2024
    Assignee: INNATE PHARMA
    Inventors: Ivan Perrot, Carine Paturel, Laurent Gauthier
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20230340143
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: February 13, 2023
    Publication date: October 26, 2023
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • RESTORATION OF T CELL ACTIVITY VIA THE CD39/CD73 AXIS
    Publication number: 20230099801
    Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.
    Type: Application
    Filed: July 28, 2022
    Publication date: March 30, 2023
    Inventors: Stéphanie CHANTEUX, Nicolas GOURDIN, Carine PATUREL, Ivan PERROT, Benjamin ROSSI
  • Compositions and methods for treating cancer
    Patent number: 11578136
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: February 14, 2023
    Assignees: INNATE PHARMA, OREGA BIOTECH
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20230025732
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: June 30, 2022
    Publication date: January 26, 2023
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
    Patent number: 11377503
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: July 5, 2022
    Assignee: INNATE PHARMA
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • ANTI-CD39 ANTIBODIES
    Publication number: 20220056145
    Abstract: The present invention relates to antigen-binding compounds that inhibit CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g. cancer.
    Type: Application
    Filed: March 10, 2021
    Publication date: February 24, 2022
    Inventors: LAURENT GAUTHIER, CARINE PATUREL, IVAN PERROT
  • CD73 BLOCKING ANTIBODIES
    Publication number: 20220041744
    Abstract: The present invention relates to antibodies, and fragments thereof, that bind and inhibit CD73. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: October 22, 2021
    Publication date: February 10, 2022
    Inventors: LAURENT GAUTHIER, CARINE PATUREL, IVAN PERROT
  • LEUCOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR NEUTRALIZING ANTIBODIES
    Publication number: 20220025056
    Abstract: This invention relates to agents that bind and neutralize the inhibitory activity of human ILT2 proteins having inhibitory activity in NK cells, T cells and/or other immune cells. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Application
    Filed: December 20, 2019
    Publication date: January 27, 2022
    Inventors: OLIVIER BENAC, STÉPHANIE CHANTEUX, IVAN PERROT, BENJAMIN ROSSI, NICOLAS VIAUD
  • COMPOUNDS AND METHODS FOR TREATMENT OF HEAD AND NECK CANCER
    Publication number: 20220025045
    Abstract: This invention relates to the use of ILT-2-targeting agents for the treatment of cancers head and neck cancers. This invention also provides advantageous combination regimens for use with ILT-2-targeting agents for the treatment of cancers.
    Type: Application
    Filed: December 20, 2019
    Publication date: January 27, 2022
    Inventors: OLIVIER BENAC, STÉPHANIE CHANTEUX, IVAN PERROT, BENJAMIN ROSSI, NICOLAS VIAUD
  • CD73 blocking agents
    Patent number: 11130817
    Abstract: Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: September 28, 2021
    Assignees: INNATE PHARMA, CENTRE LÉON BÉRARD
    Inventors: Christophe Caux, Laurent Gauthier, Nicolas Gourdin, Christine Menetrier-Caux, Carine Paturel, Ivan Perrot
  • CD73 BLOCKADE
    Publication number: 20200392243
    Abstract: This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5? nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.
    Type: Application
    Filed: September 2, 2020
    Publication date: December 17, 2020
    Inventors: IVAN PERROT, CARINE PATUREL, LAURENT GAUTHIER
  • MICA BINDING AGENTS
    Publication number: 20200299380
    Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: February 28, 2020
    Publication date: September 24, 2020
    Inventors: Mathieu Blery, Laurent Gauthier, Ivan Perrot, Cecile Bonnafous
  • CD73 blockade
    Patent number: 10766966
    Abstract: This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5? nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: September 8, 2020
    Assignee: INNATE PHARMA
    Inventors: Ivan Perrot, Carine Paturel, Laurent Gauthier
  • Mica binding agents
    Patent number: 10577416
    Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: March 3, 2020
    Assignee: Innate Pharma, S.A.
    Inventors: Mathieu Blery, Laurent Gauthier, Ivan Perrot, Cecile Bonnafous
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20200024357
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: June 17, 2019
    Publication date: January 23, 2020
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20190389961
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: March 16, 2018
    Publication date: December 26, 2019
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • CD73 BLOCKING AGENTS
    Publication number: 20190225703
    Abstract: Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.
    Type: Application
    Filed: October 11, 2016
    Publication date: July 25, 2019
    Inventors: CHRISTOPHE CAUX, LAURENT GAUTHIER, NICOLAS GOURDIN, CHRISTINE MENETRIER-CAUX, CARINE PATUREL, IVAN PERROT
  • POTENTIATING THE EFFECT OF ATP RELEASE
    Publication number: 20190218304
    Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 in the treatment of cancer to potentiate the activity of an agent or treatment that induces the extracellular release of ATP from tumor cells and/or induces the death of tumor cells.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 18, 2019
    Inventors: Stéphanie CHANTEUX, Nicolas GOURDIN, Carine PATUREL, Ivan PERROT, Benjamin ROSSI
  • RESTORATION OF T CELL ACTIVITY VIA THE CD39/CD73 AXIS
    Publication number: 20190218308
    Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 18, 2019
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi